E-viri
Recenzirano
Odprti dostop
-
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variantEdara, Venkata Viswanadh; Norwood, Carson; Floyd, Katharine; Lai, Lilin; Davis-Gardner, Meredith E.; Hudson, William H.; Mantus, Grace; Nyhoff, Lindsay E.; Adelman, Max W.; Fineman, Rebecca; Patel, Shivan; Byram, Rebecca; Gomes, Dumingu Nipuni; Michael, Garett; Abdullahi, Hayatu; Beydoun, Nour; Panganiban, Bernadine; McNair, Nina; Hellmeister, Kieffer; Pitts, Jamila; Winters, Joy; Kleinhenz, Jennifer; Usher, Jacob; O’Keefe, James B.; Piantadosi, Anne; Waggoner, Jesse J.; Babiker, Ahmed; Stephens, David S.; Anderson, Evan J.; Edupuganti, Srilatha; Rouphael, Nadine; Ahmed, Rafi; Wrammert, Jens; Suthar, Mehul S.
Cell host & microbe, 04/2021, Letnik: 29, Številka: 4Journal Article
The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising concerns about the efficacy of infection- or vaccine-induced antibodies. We compared antibody binding and live virus neutralization of sera from naturally infected and Moderna-vaccinated individuals against two SARS-CoV-2 variants: B.1 containing the spike mutation D614G and the emerging B.1.351 variant containing additional spike mutations and deletions. Sera from acutely infected and convalescent COVID-19 patients exhibited a 3-fold reduction in binding antibody titers to the B.1.351 variant receptor-binding domain of the spike protein and a 3.5-fold reduction in neutralizing antibody titers against SARS-CoV-2 B.1.351 variant compared to the B.1 variant. Similar results were seen with sera from Moderna-vaccinated individuals. Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B.1.351, suggesting that protective humoral immunity may be retained against this variant. Display omitted •Antibodies from infected and vaccinated individuals bind to the B.1.351 RBD•Convalescent sera through eight months can neutralize the B.1.351 variant•Serum from vaccinated individuals retains neutralization against the B.1.351 variant In this study, Edara et al. (2021) report that, despite reduced antibody binding to the B.1.351 RBD, sera from infected (acute and convalescent) and Moderna (mRNA-1273)-vaccinated individuals were still able to neutralize the SARS-CoV-2 B.1.351 variant, suggesting that protective humoral immunity may be retained against this variant.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.